Searchable abstracts of presentations at key conferences in endocrinology

ea0049ep970 | Pituitary - Clinical | ECE2017

Somatostatin analogues-induced diabetes mellitus in acromegalic patients reverts after drug withdrawal: a long-term study

Cappellani Daniele , Urbani Claudio , Sardella Chiara , Marconcini Giulia , Marcocci Claudio , Rossi Giuseppe , Bogazzi Fausto

Context: Therapy with somatostatin analogues (SSAs) may have deleterious effects on glucose metabolism in patients with acromegaly, often leading to development of diabetes mellitus (DM).Aim of the study: To evaluate whether DM, which developed during therapy with SSAs, may revert after drug withdrawal and cure of acromegaly with pituitary adenomectomy.Design: Retrospective cohort study, in a tertiary referral center.<p class="...

ea0022p606 | Neuroendocrinology and Pituitary (<emphasis role="italic">Generously supported by Novartis</emphasis>) | ECE2010

Impact of rosiglitazone on serum IGF1 concentrations in uncontrolled acromegalic patients under conventional medical therapy: results from a pilot phase 2 study

Lombardi Martina , Rossi Giuseppe , Raggi Francesco , Urbani Claudio , Sardella Chiara , Cosci Chiara , Martino Enio , Bogazzi Fausto

Current therapies for acromegaly are unsatisfactory for some patients. High dose thiazoledinedines have been reported to shrink tumor size and reduce serum GH levels in animal models of acromegaly. To study the effects of increasing doses of rosiglitazone on serum GH and IGF1 concentrations in acromegalic patients, we designed a phase two clinical trial. We enrolled five consecutive patients with active acromegaly uncontrolled under conventional therapies. They received increa...

ea0022p451 | Endocrine tumours &amp; neoplasia (<emphasis role="italic">Generously supported by Novartis</emphasis>) | ECE2010

Prokineticin 1 stimulates prostate epithelial cell migration and proliferation in vitro

Visonti Daniela , Bellastella Giuseppe , Rossi Valentina , Chieffi Paolo , Maione Luigi , Punzo Paola , Bellastella Antonio , Sinisi Antonio Agostino

Prokineticin 1 (Prok1), the product of EGVEGF/PROK 1 gene, acts through two G-coupled receptors (PKR1 and PKR2) and is involved in a wide spectrum of actions, including tumorigenesis. Increased Prok1 expression has been found in prostate hyperplasia and cancer, suggesting a role in prostate cancer and BPH. Aim of this study was to elucidate the role of Prok1 on prostate cell function and growth. We evaluated the effects of Prok1 on epithelial prostate cell (PC) migration and p...

ea0016p343 | Endocrine tumours | ECE2008

Raloxifene induces growth arrest and apoptosis in prostate cell lines expressing both ERα and β

Bellastella Giuseppe , Rossi Valentina , Visconti Daniela , Palumbo Vincenzo , Chieffi Paolo , Staibano Stefania , Mascolo Giuseppe , Preziosi Domenico , Bellastella Antonio , Sinisi Antonio Agostino

Raloxifene (RAL) is a selective estrogen receptor (ER) modulator (SERM) proposed for chemoprevention of breast cancer and osteoporosis. SERMs exert agonist–antagonist effects depending on tissue or ERs expressed. RAL induces apoptosis in both androgen-dependent and independent cell lines, suggesting a selective activation of ERβ and prevalent antagonist effect on ERα in prostate cells (PC). In this study we evaluated effects of estradiol (E2) and RAL on epitheli...

ea0041ep883 | Pituitary - Clinical | ECE2016

Disease activity and lifestyle influence the occurrence of cardiovascular risk factors and cardiovascular events in acromegaly

Sardella Chiara , Cappellani Daniele , Urbani Claudio , Manetti Luca , Marconcini Giulia , Tomisti Luca , Lupi Isabella , Rossi Giuseppe , Scattina Ilaria , Lombardi Martina , Di Bello Vitantonio , Marcocci Claudio , Martino Enio , Bogazzi Fausto

Context: Acromegalic patients have a high-risk cardiovascular profile. However, the determinants of cardiovascular risk factors and major cardiovascular events (MACE), which may develop after diagnosis of acromegaly, are not fully understood.Objectives: To identify the predictors for systemic comorbidities and MACE, after diagnosis of disease. The role of therapy for acromegaly on the occurrence of such complications was also evaluated.<p class="abst...